Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-world effectiveness of Lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice. Cancer Rep (Hoboken). 2023 Jan;6(1):e1679. doi: 10.1002/cnr2.1679
Peay HL, Fischer R, Mange B, Paquin RS, Smith EC, Sadosky A, Russo L, Ricotti V, Rensch C, Morris C, Martin AS, Ganot A, Beaverson K, Mansfield C. Patients' and caregivers' maximum acceptable risk of death for non-curative gene therapy to treat Duchenne muscular dystrophy. Mol Genet Genomic Med. 2021 May;9(5):e1664. doi: 10.1002/mgg3.1664
Dardis G, Tryon R, Ton Q, Johnson SL, Lovine MK. Cx43 suppresses evx1 expression to regulate joint initiation in the regenerating fin. Dev Dyn. 2017 Sep;246(9):691-9. doi: 10.1002/dvdy.24531
Brubaker L, Richter HE, Barber MD, Hsu Y, Rahn DD, Menefee S, Visco A, Spino C, Martin S, Meikle SF. Pelvic floor disorders clinical trials: participant recruitment and retention. Int Urogynecol J. 2013 Jan 1;24(1):73-9.